Frazier Financial Advisors, LLC Viking Therapeutics, Inc. Transaction History
Frazier Financial Advisors, LLC
- $129 Billion
- Q3 2024
A detailed history of Frazier Financial Advisors, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Frazier Financial Advisors, LLC holds 48 shares of VKTX stock, worth $2,908. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48
Previous 48
-0.0%
Holding current value
$2,908
Previous $2.55 Million
19.41%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
479Shares Held
66.3MCall Options Held
5.9MPut Options Held
2.96M-
Vanguard Group Inc Valley Forge, PA10.2MShares$616 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$365 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$310 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$128 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$113 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.65B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...